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security and several private insurance agencies. The regulatory
and functional differences between those agencies make drug
reimbursement regulations complicated for the health care pro-
fessionals and patients. Turkish Society of Clinical Pharmacol-
ogy organized a three-day meeting with all stakeholders
(parliamentarians, academicians, Ministry of Health, Ministry of
Finance, State Planning Organization, international and local
drug industry representatives and social security institutions,
medical and pharmacist associations) for discussion of the
present reimbursement system and its future. METHODS: Dis-
cussion was performed in six steps. First, representatives of the
stakeholders presented their own policies and problems. Second,
a brainstorm was performed. All the ideas were recorded as a
consensus text in the third step. The next day, participants were
divided into four groups to evaluate the text at a round table dis-
cussion. Finally, collecting all the suggestions, the consensus text
was rewritten and distributed to the representatives after the
meeting to ask for their approval. RESULTS: All stake holders,
except multinational drug companies, were agreeing to use
national pharmacoeconomic data for reimbursement issues.
Other main outcomes of this consensus meeting accepted by all
the representatives were as follows: All health care professionals
should get enough education to establish the rational use of
drugs. An autarchic “National Drug Institution” should be built.
CONCLUSIONS: A “Reimbursement Commission” should be
built with the participation of all representatives and should
work for the standardization of reference drug prices. State
funded social insurance systems should be kept under one valid
insurance system. OTC drug deﬁnition and the OTC drug list
should be deﬁned clearly, and preventive therapy such as vacci-
nation should be reimbursed in full.
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OBJECTIVES: Comparative analysis and productivity measure-
ment of outpatient care, provided and reimbursed by IKA, the
largest National Social Insurance Institution in Greece. In-house
services of Patission Local Health Unit (LHU)) are compared to
Family Doctor’s private surgeries’ medical visits (out-sourcing
services). METHODS: A prospective study of medical visits for
a 6 month period (September 1, 2002 to February 28, 2003).
Sample consisted of 23,982 outpatient visits to 3 specialities (5
Cardiologists with 12,538 visits, 3 Surgeons with 4544 visits and
3 Otolaryngologists with 6900 visits) offering their services in a
LHU and 3 family doctors with 17,295 visits, belonging to the
same LHU but offering their services in their private surgeries
with 2942, 8245, and 6105 visits respectively. Clinical and eco-
nomic data is derived from IKA’s Central Administration, its
Information System, from LHU and interviews with executives.
RESULTS: Productivity among all doctors presented signiﬁcant
divergences. The productivity of family doctors in their private
surgeries was higher than LHU’s doctors while the average
waiting time appeared to be higher for medical visits to LHU’s
doctors. Average cost of medical visits to the LHU was estimated
at 8.48€ while cost per speciality was 7.19€ for the cardiologist,
10.43€ for the surgeon and 7.83€ for the otolaryngologist.
Average cost per visit to family doctors was 2.33€, while cost per
specialty was 3.69€, 1.53€ and 1.77€ respectively. CONCLU-
SIONS: Average cost of medical visit to family doctor’s private
surgery was lower than the cost of medical visit to LHU’s. The
provision of outpatient medical care offered by IKA through out-
sourcing seems to be most cost-effective. Economic evaluation
studies, combining the efﬁcient use of health resources with the
adoption of effective patterns of patients’ management, should
be conducted at national level by all social funds and incorpo-
rated in their decision making process.
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OBJECTIVE: To examine the time of occurrence, type and cost
of injuries resulting from bicycle accidents treated in Emergency
Departments (ED). METHODS: Cases were identiﬁed from
2002 ED and hospital databases from Massachusetts using ICD-
9 diagnosis and E-codes (E826.0–E826.9). Hospital cases were
limited to those admitted via the ED. Cost estimates include facil-
ity, accommodations and ancillary services, reported in 2002
US$. Charges were adjusted using a 0.61 cost-to-charge ratio.
RESULTS: Of 10,025 bicycle accident cases identiﬁed, 75% were
male. Mean age was 28 years (median: 15, range: <1–98), 61%
were under 20 years. Transport by ambulance was used for 13%
of those injured; <1% by helicopter. The cyclist was the injured
party in 96% of cases; a pedestrian or other person in 4%.
Almost half (48%) arrived between 4:00 and 9:00 PM, 36% on
a weekend and 70% during May–September. The majority
(94%) were treated and released from ED, 2% died in ED, 3%
were admitted to hospital; and 1% were either transferred to
another facility, or left AMA. Highest admission rate (12%) 
was seen in older patients (60+ years). Skull fractures and other








locations and sprains represented 37%, 27% were mainly 
contusions/abrasions, 23% had open wounds, and <1% major
abdominal injury. The visit reason codes for the remaining cases
included pain, other symptoms and conditions. Mean duration
of ED visit was 2.3 hours (median: 1.8). Mean cost per ED visit
was $460 (median: $325) for those treated and released and
$560 for those admitted (median: $427). On average, those
admitted spent 3 days (median: 2) in the hospital at a cost of
$8375 (median: $6340). CONCLUSIONS: Most bicycle related
injuries occurred in children or young adults,in the early evening,
involved only the cyclist and could be managed in the ED.
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OBJECTIVES: Drug costs represent a considerable cost item 
in the overall hospital budget. Within drug costs, oral and
injectable antibiotics are indeed one of the most relevant sources
of expenditure. This analysis is focused on the comparison
between the actual per patient consumption of antibiotics and
the Deﬁned Daily Dose (DDD) which is frequently used as an
indicator for inclusion of a drug in the Hospital Formulary and
subsequent purchase. METHODS: This research was based on
the analysis of the Antibiotics Request Forms (ARF’s), which
were forwarded by the Hospital Wards to the Pharmacy in the
Geriatric Hospital “U. Sestilli”, Ancona. The analysis was
focused on the daily per patient consumption (Prescribed Daily
Doses, PDD) of antibiotic treatments as compared to the DDD,
and on its cost (considering ofﬁcially published prices and hos-
pital discounts). RESULTS: In the period February–May, 2003,
2350 ARF’s were ﬁled, referring to prescriptions of antibiotics.
Of these, 1942 were eligible for analysis and concerned 976
patients. Total expenditure for antibiotics in such period was
63,727€; 25% of this was due to the ﬂuorochinolones currently
included in the Hospital Formulary (ATC J01MA): ciproﬂoxacin
and levoﬂoxacin. By comparing PDD’s with DDD’s, and assum-
ing equal to one the exact correspondence between PDD and
DDD of each drug, in 75% of prescriptions PDD’s did not cor-
respond to DDD’s. In particular, the PDD/DDD rate resulted
0.68 for injectable ciproﬂoxacin, and 1.1 for injectable lev-
oﬂoxacin: similarly, considering oral formulations, the two rates
were respectively 0.79 and 1.28. CONCLUSIONS: According to
the prescription practice of this Hospital and to the type of
patients seen, the inclusion in Hospital Formulary and purchase
of antibiotics based on the DDD’s might be misleading and could
result into an incoherent management of Pharmacy stock and
ﬁnancial assets.
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OBJECTIVES: The new G-DRG hospital payment system came
into effect in 2003. For a fully functional DRG-payment system
it is important that DRG groups are cost homogenous.
METHODS: To show the impact of innovations on the cost
homogenity of a DRG group, a cost study has been performed
as a sub-study of a clinical safety and feasibility analysis.
RESULTS: We used the bone growth protein rhBMP-2 (not yet
approved for Spine indication in Europe) additional to standard
fusion for spine surgery in 18 cases. RhBMP-2 has the potential
to reduce complication rates, avoids iliac crest bone graft har-
vesting and associated morbidities and ensures earlier return to
work. The relevant DRG for fusion procedures in our patient
group—with or without the usage of rhBMP-2—is I09B, relative
weight 2.875 and average costs of 8313.94€. Average costs have
been assessed in 536 patients. In our study we have assessed the
cost for spine fusions with and without the usage of rhBMP-2.
All costs have been calculated according to IneK calculations
rules. Average cost were in the none rhBMP-2 group 8388.41€
with average implant costs of 2576.17€. The results reﬂect very
well cost homogenity in the DRG group. Usage of rhBMP-2 adds
signiﬁcant drug cost (3422€). No signiﬁcant other cost offsets
apply. A total cost increase of 40.79% leads to an unacceptable
high cost variance in the I09B. CONCLUSIONS: Based on this
data one could conclude that specialized hospital wards in spine
surgery who attract more difﬁcult cases will be discriminated in
the G-DRG system as they will more often have to use innova-
tive high price drugs or medical devices. An expanded list of sup-
plementary fees for high cost innovative technologies could help
to reduce the costvariance within one DRG without the need to
further differentiate DRG groups.
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OBJECTIVES: Critical leg ischemia affects between 1.5 and 5%
of the population over 50 years old. Before opting for limb
amputation, two alternative therapies can be carried out: drug
therapy with prostanoid or Spinal Cord Stimulation (SCS). This
project, developed in the department of vascular surgery of the
Ospedale Maggiore in Bologna, was aimed at evaluating the
annual impact of these two treatments on department budget.
The annual impact of a therapy on department budget is deﬁned
as the difference between the cost of production and the DRG.
METHODS: The therapies cost of production was assessed
through an Activity Based Management (ABM) and Activity
Based Costing (ABC) approach. Activities were identiﬁed by
informal interviews with all hospital staff involved in the treat-
ment process. Costs were assessed by analyzing accounting data
supplied by the hospital administrative services. RESULTS: The
SCS pathway consists of two 3-days hospitalizations. Total cost
of SCS treatment was 10,390€ for responder patients (RP) and
3181.11€ for non-responders (NRP). Reimbursement for RP
consists of 2 DRG 4 6.430€ and DRG 4 + DRG 461 (2797.13€)
for NRP. The prostanoid pathway consists of one hospitalization
lasting between 7 and 28 days. This hospitalization can be
repeated if the clinical condition of the patient does not improve
after the ﬁrst cycle of treatment. The cost of this treatment varies
from a minimum of 4445.73€ for a cycle of 7 days to a maximum
of 9118.73€ for a 28 days cycle. Hospitalization for prostanoid
therapy is reimbursed by DRG 130 (3524.82€) or by DRG 131
(2443.36€). CONCLUSIONS: SCS costs are fully covered by
DRG while drug therapy costs are only partially covered.
Besides, the treatments differ as regards to the ability to forecast
patient total costs before starting treatment, which is low for
prostanoid therapy and high for SCS therapy.
